Balancing Gastroprotection and Cardioprotection with Selective Cyclo-Oxygenase-2 Inhibitors: Clinical Implications

Drug Safety

Volumn 26, Issue 13, 2003, Pages 913-924

  Meagher, Emma A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE EXACERBATION; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; NEPHROTOXICITY; OSTEOARTHRITIS; PAIN; PEPTIC ULCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SODIUM RETENTION; STOMACH PROTECTION; WATER RETENTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; HEART; HUMANS; ISOENZYMES; KIDNEY; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0142154979     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326130-00001     Document Type: Review

References (69)

1. Celebrex (celecoxib). US Product Information. Peapack (NJ): Pharmacia, 2001
2. Goldenberg M. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999; 21: 1497-513
3. Scott L, Lamb H. Rofecoxib. Drugs 1999; 58: 499-507
4. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-91
5. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345 (6): 433-42
6. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem 1999; 274: 22903-6
7. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120
8. Wang LH, Hajibeigi A, Xu XM, et al. Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Commun 1993; 190: 406-11
9. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60
10. Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm 1996; 5: 305-23
11. Crofford LJ, Wilder RL, Ristimäki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101
12. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-91
13. Gimbrone Jr MA, Topper JN, Nagel T, et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000 May; 902: 230-9
14. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 [published erratum appears in Proc Natl Acad Sci U S A 1999; 96: 5890]. Proc Natl Acad Sci U S A 1999; 96: 272-7
15. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-41
16. McAdam BF, Mardini I, Habib A, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000; 105: 1473-82
17. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002 May 28; 99 (11): 7634-9
18. Tanaka A, Hase S, Miyazawa T, et al. Upregulation of cyclooxygenase 2 by inhibition of cyclooxygenase 1: a key to nonsteroidal anti-inflammatory drug induced intestinal damage. J Pharm Exp Ther 2002; 300: 754-61
19. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002 Jul; 110 (1): 61-9
20. FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest 2002 Jul; 110 (1): 33-4
21. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991 Jun; 5 (9): 2304-12
22. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-6
23. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
25. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthase. J Pharmacol Exp Ther 1994; 271: 1705-12
26. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21
27. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for COX-1 rather than COX-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-8
28. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336-47
29. Malmstrom K, Daniels S, Kotey P, et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo-and active-comparator-controlled clinical trial. Clin Ther 1999; 21: 1653-63
30. Morrison BW, Daniels SE, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999; 94: 504-8
31. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-8
32. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 1781-7
33. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-8
34. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002 Feb 20; 94 (4): 252-66
35. Akashi H, Han HJ, Iizaka M, et al. Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer 2000 Dec 15; 88 (6): 873-80
36. Thomas T, Nadackal TG, Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001 Oct 29; 12 (15): 3263-7
37. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, et al. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001 Mar; 76 (6): 1895-904
38. Broe GA, Grayson DA, Creasey HM, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000 Nov; 57 (11): 1586-91
39. North GL. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother 2001 Dec; 35 (12): 1638-43
40. Fournier DB, Gordon GB. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem 2000; 77 (S34): 97-102
41. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52
42. Seno H, Oshima M, Ishikawa TO, et al. Cyclooxygenase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc (Delta 716) mouse intestinal polyps. Cancer Res 2002 Jan 15; 62 (2): 506-11
43. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000 Sep 1; 60 (17): 4705-8
44. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99
45. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83
46. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55
47. Hawkey C, Laine L, Simon T, et al. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 370-7
48. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55
49. Bombardier C, Laine L, Reicin A. Comparison of upper gastrointestinal toxicity of refecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
50. FDA Advisory Committee. Briefing Information: NDA 21-042/s007 Vioxx (rofecoxib) (2001). Available from URL: http:// www.fda.gov./ohrms/docket/ac/ cdero/htm arthritis [Accessed 2002 Feb 28]
51. FDA Advisory Committee. Briefing Information: NDA 20-998/s009 Celebrex (celecoxib) (2001). Available from URL: http:// www.fda.gov [Accessed 2002 Feb 28]
52. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? BMJ 2002; 324 (7349): 1287-8
53. FitzGerald GA, Smith B, Pedersen AK, et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-8
54. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002 Apr 19; 296 (5567): 539-41
55. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51
56. McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-4
57. Wallberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71
58. Watson DJ, Rhodes T. Higher incidence of thromboembolic events among patients with rheumatoid arthritis vs osteoarthritis, and vs. no arthritis, in the general practice research database (GPRD) [abstract OP0109]. Presented at the Annual European Congress of Rheumatology; 2001 Jun 13-16; Prague, Czech Republic
59. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001 Nov 6; 104 (19): 2280-8
60. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003 Jun; 125 (6):1481-92
61. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20
62. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382-7
63. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9
64. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-23
65. Kimmel SE, Berlin JA, Reilly M, et al. Lower myocardial infarction risk amongst current users of non-aspirin non steroidal anti-inflammatory medications [abstract]. J Am Coll Cardiol 2002; 39: 318A
66. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000 Jul 4; 133 (1): 1-9
67. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclo-oxygenase-2 inhibitor. Am J Ther 2000; 7 (3): 139-75
68. Whelton A. Renal aspects of treatment with non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2-specific inhibitors. Am J Med 2001; 110 Suppl. 3A: S33-S42
69. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000 Jan 18; 132 (2): 134-43